Terms: = Gastric cancer AND SLC34A2, ENSG00000157765, O95436, NPTIIb, NAPI-IIb, NAPI-3B, FLJ90534, 10568
5 results:
1. slc34a2 promotes cancer proliferation and cell cycle progression by targeting TMPRSS3 in colorectal cancer.
Yang Y; Wu J; Yu X; Wu Q; Cao H; Dai X; Chen H
Pathol Res Pract; 2022 Jan; 229():153706. PubMed ID: 34929599
[TBL] [Abstract] [Full Text] [Related]
2. slc34a2 regulates miR-25-Gsk3β signaling pathway to affect tumor progression in gastric cancer stem cell-like cells.
Zhang L; Guo X; Zhang L; Yang F; Qin L; Zhang D; Qin Y
Mol Carcinog; 2018 Mar; 57(3):440-450. PubMed ID: 29178392
[TBL] [Abstract] [Full Text] [Related]
3. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
Roskoski R
Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
[TBL] [Abstract] [Full Text] [Related]
4. Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of slc34a2 and Raf/MEK/ERK pathway.
Zhang JX; Xu Y; Gao Y; Chen C; Zheng ZS; Yun M; Weng HW; Xie D; Ye S
Mol Cancer; 2017 Jan; 16(1):18. PubMed ID: 28114937
[TBL] [Abstract] [Full Text] [Related]
5. Identification of ROS1 rearrangement in gastric adenocarcinoma.
Lee J; Lee SE; Kang SY; Do IG; Lee S; Ha SY; Cho J; Kang WK; Jang J; Ou SH; Kim KM
Cancer; 2013 May; 119(9):1627-35. PubMed ID: 23400546
[TBL] [Abstract] [Full Text] [Related]
